<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209299</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000683300</org_study_id>
    <secondary_id>ECOG-E2603T1</secondary_id>
    <nct_id>NCT01209299</nct_id>
  </id_info>
  <brief_title>Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate</brief_title>
  <official_title>Integrated Molecular Signature for the Prediction of Response to Carboplatin/Paclitaxel-Based Chemotherapy in Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ECOG-ACRIN Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of tissue in the laboratory from patients receiving carboplatin&#xD;
      and paclitaxel with or without sorafenib tosylate may help doctors learn more about the&#xD;
      effects of this treatment on cells. It may also help doctors understand how well patients&#xD;
      respond to treatment.&#xD;
&#xD;
      PURPOSE: This research study is studying biomarkers in predicting response to chemotherapy in&#xD;
      patients with advanced or metastatic melanoma previously treated with carboplatin and&#xD;
      paclitaxel with or without sorafenib tosylate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  To independently correlate the gene expression and promoter methylation profiles to&#xD;
           chemotherapy response in patients with advanced or metastatic melanoma treated with&#xD;
           carboplatin and paclitaxel with versus without sorafenib on clinical trial ECOG-E2603.&#xD;
&#xD;
        -  To develop a predictive model of chemotherapy response utilizing integrated analysis of&#xD;
           gene expression and promoter methylation data.&#xD;
&#xD;
        -  To evaluate whether the NER pathway haplotypes are associated with platinum drug&#xD;
           resistance and survival.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Archived paraffin-embedded tissue samples are analyzed for gene expression and promoter&#xD;
      methylation profiles, and genes involved in the NER pathway.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2012</start_date>
  <completion_date type="Actual">February 19, 2012</completion_date>
  <primary_completion_date type="Actual">February 19, 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between gene expression and promoter methylation profiles to chemotherapy response</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <enrollment type="Actual">80</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>DNA methylation analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Samples from patients enrolled on E2603 from whom samples were submitted for research&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of melanoma&#xD;
&#xD;
               -  Unresectable locally advanced or stage IV disease&#xD;
&#xD;
          -  Received carboplatin and paclitaxel with versus without sorafenib on clinical trial&#xD;
             ECOG-E2603&#xD;
&#xD;
          -  Archived paraffin-embedded tissue samples&#xD;
&#xD;
               -  Responder (complete or partial response, or stable disease) and non-responder&#xD;
                  (disease progression or unavailable)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hussein A. Tawbi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>May 16, 2017</last_update_submitted>
  <last_update_submitted_qc>May 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IIIC melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

